Literature DB >> 24648247

Role of cardiac catheterization and percutaneous coronary intervention in the preoperative assessment and management of patients before orthotopic liver transplantation.

Haripriya Maddur1, Patrick D Bourdillon, Suthat Liangpunsakul, A Joseph Tector, Jonathan A Fridell, Marwan Ghabril, Marco A Lacerda, Charlotte Bourdillon, Changyu Shen, Paul Y Kwo.   

Abstract

Limited data regarding the optimal risk assessment strategy for evaluating candidates for orthotopic liver transplantation (OLT) exist. Our center has adopted a policy of performing cardiac catheterization (CATH) in patients with predefined risk factors, and this is followed by percutaneous coronary intervention (PCI) when it is indicated, even in the presence of negative stress test findings. The aim of this single-center, retrospective study of all patients who underwent OLT between 2000 and 2010 was to assess the effect of our policy on cardiovascular (CV) complications and survival rates after OLT. Data, including 1-year all-cause and CV mortality, postoperative myocardial infarctions (MIs), and frequencies of CATH and PCI, were abstracted. The study was divided into 3 subperiods to reflect the changes in policy over this period: (A) 2000-2004, (B) 2005-2008, and (C) 2009-2010. One thousand two hundred twenty-one patients underwent OLT between 2000 and 2010. The rate of catheterization increased during the 3 time periods (P < 0.001), as did the rate of PCI (P < 0.05). All-cause mortality decreased over the periods (P < 0.001), as did the MI rate (P < 0.001). Thirty-five of the 57 patients requiring PCI had normal stress tests. The mortality rate associated with postoperative MIs was significantly higher than the overall all-cause mortality rate. In conclusion, a significant improvement in the overall survival rate over the 3 analyzed time periods was noted. Increases in the frequencies of CATH and PCI corresponded to significant reductions in postoperative MIs and 1-year all-cause mortality rates. The increased use of CATH and PCI was associated with reduced overall all-cause mortality through reductions in the incidence of both fatal and nonfatal MIs. Further analyses of the role of stress testing and CATH in evaluating and treating patients before OLT are required to optimize this process.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24648247     DOI: 10.1002/lt.23873

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  17 in total

Review 1.  PRO: Cardiac Catheterization Is the Optimal Strategy for Cardiovascular Risk Stratification in This Patient.

Authors:  Brett Sadowski; Tilak Baba; Amol S Rangnekar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

2.  Outcome of Liver Transplant Recipients With Revascularized Coronary Artery Disease: A Comparative Analysis With and Without Cardiovascular Risk Factors.

Authors:  Sanjaya K Satapathy; Jason M Vanatta; Ryan A Helmick; Albert Flowers; Satish K Kedia; Yu Jiang; Bilal Ali; James Eason; Satheesh P Nair; Uzoma N Ibebuogu
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 3.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 4.  Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.

Authors:  James Philip G Esteban; Amon Asgharpour
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

Review 5.  Cardiac evaluation of the kidney or liver transplant candidate.

Authors:  Paul Emile Levy; Sadiya S Khan; Lisa B VanWagner
Journal:  Curr Opin Organ Transplant       Date:  2021-02-01       Impact factor: 2.640

Review 6.  Cardiac imaging for the assessment of patients being evaluated for liver transplantation.

Authors:  Kameel Kassab; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2021-04-06       Impact factor: 3.872

Review 7.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

Review 8.  Metabolic and cardiovascular complications in the liver transplant recipient.

Authors:  Laura De Luca; Rachel Westbrook; Emmanuel A Tsochatzis
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

9.  Effectively Screening for Coronary Artery Disease in Patients Undergoing Orthotopic Liver Transplant Evaluation.

Authors:  Bryan C Lee; Feng Li; Adam J Hanje; Khalid Mumtaz; Konstantinos D Boudoulas; Scott M Lilly
Journal:  J Transplant       Date:  2016-06-22

Review 10.  Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.

Authors:  Pranab M Barman; Lisa B VanWagner
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.